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Abstract
Background: Whooping cough is a respiratory disease caused by Bordetella pertussis, which induces mucosal IgA antibodies
that appear to be relevant in protection. Serum IgA responses are measured after pertussis infection and might provide an
additional role in pertussis diagnostics. However, the possible interfering role for pertussis vaccinations in the induction of
serum IgA antibodies is largely unknown.
Methods/Principal Findings: We compared serum IgA responses in healthy vaccinated children between 1 and 10 years of
age with those in children who despite vaccinations recently were infected with Bordetella pertussis. All children have been
vaccinated at 2, 3, 4 and 11 months of age with either the Dutch whole-cell pertussis (wP) vaccine or an acellular pertussis
(aP) vaccine and additionally received an aP booster vaccination at 4 years of age. Serum IgA responses to pertussis toxin
(PT), filamentous heamagglutinin (FHA) and pertactin (Prn) were measured with a fluorescent multiplex bead-based
immuno-assay. An ELISPOT-assay was used for the detection of IgA-memory B-cells specific to these antigens. Serum IgA
levels to all pertussis vaccine antigens were significantly higher in infected children compared with healthy children. High
correlations between anti-PT, anti-FHA or anti-Prn IgA and IgG levels were found in infected children and to some degree in
wP primed children, but not at all in aP primed children. Highest numbers of IgA-pertussis-specific memory B-cells were
observed after infection and generally comparable numbers were found after wP and aP vaccination.
Conclusions: This study provides new insight in the diagnostic role for serum IgA responses against PT in vaccinated
children. Since aP vaccines induce high serum IgG levels that interfere with pertussis diagnostics, serum IgA-PT levels will
provide an additional diagnostic role. High levels of serum IgA for PT proved specific for recent pertussis infection with
reasonable sensitivity, whereas the role for IgA levels against FHA and Prn in diagnosing pertussis remains controversial.
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Introduction
B.pertussis establishes infection by attaching to epithelial cells on
the human respiratory tract, where toxins are released that cause
local and systemic damage [1]. At the mucosal surface, secretory
IgA, a dimeric complex, represents the predominant antibody
isotype and functions as a first line of defense. The role of serum
IgA is less clear. Circulating serum IgA is mainly monomeric and
is considered a second line of defense, mediating elimination of
pathogens that have breached the mucosal surface [2]. Serum IgA
facilitates antibody-dependent cell-mediated cytotoxity and phago-
cytosis. However, information about the induction of serum IgA
and its role after either pertussis vaccination or infection in
children is complicated to interpret. Previous studies showed an
increase in serum anti-pertussis IgA responses after infection, but
not after whole-cell (wP) vaccination in children and adults
[3,4,5,6,7,8,9]. In contrast, others demonstrated increased IgA
responses to the pertussis vaccine components after acellular
pertussis (aP) vaccination in adolescents and adults [10,11,12].
However, these serum IgA responses might result from earlier
priming by (subclinical) infection. Since the last two decades
whooping cough is reemerging in countries with widespread
pertussis vaccination coverage, especially in the adolescent and
adult population. In most of these countries a wP pertussis vaccine
was replaced by an aP vaccine in the 1990s. A serum IgG level
against PT above 50–100 IU/ml is currently used for pertussis
diagnostics [13]. However, aP vaccines also induce high IgG-PT
levels that interfere with pertussis diagnostics. Whether the value
of anti-pertussis IgA levels could be indicative for recent infection
with B.pertussis is a long topic of debate and the possible interfering
PLoS ONE | www.plosone.org 1 November 2011 | Volume 6 | Issue 11 | e27681effects of wP and aP vaccinations on the interpretation of IgA
results have not been studied before. Therefore, we evaluated the
IgA responses to pertussis toxin (PT), filamentous heamagglutinin
(FHA) and pertactin (Prn) in children between 1 and 10 years of
age who were vaccinated with either the Dutch wP or aP vaccine
at 2, 3, 4 and 11 months of age and additionally received an aP
preschool booster vaccination. We compared serum IgA levels in
healthy vaccinated children with those in vaccinated children of
the same ages who despite previous vaccinations recently were
infected with B.pertussis.
Methods
Ethics Statement
All studies were conducted according to the Declaration of
Helsinki, Good Clinical Practice Guidelines with the approval of
the relevant ethics review committee (Medisch Ethische Toes-
tingscommissie (METC) in Almere, the Netherlands and the
Central Committee on Research Involving Human Subjects
(CCMO), the Hague, the Netherlands). Written informed consent
was obtained from parents or legal representatives before the start
of the study.
Study population
Healthy children of different ages (12 months, 3, 4, 6 and 9
years) included in this study originated from three different cohort
studies; (1) 51 children 12 months of age from whom one blood
sample was taken at one month after the routine 4
th vaccination at
11 months (ISRCTN97785537); (2) 580 children of 3, 4 or 6 years
of age with one blood sample at the presented ages or children
aged 4 years with one blood sample either before or 10 days or 28
days after the preschool booster vaccination (ISRCTN65428640)
[14]; 75 children 9 years of age with sequential blood samples
before, one month and one year after a second aP booster
vaccination at 9 years of age (ISRCTN64117538) (figure 1). In
addition, a fourth cohort consisted of 73 children 1 to 10 years of
age who were vaccinated according to the national immunization
program (NIP, see below) but in whom a recent pertussis infection
was diagnosed [15]. Recent pertussis infection was defined as
having a high single serum anti-IgG-PT level (.100 U/ml) or a
positive PCR confirmation. One blood sample was taken per child
on average 42 days (range 3–119 days) after the first symptoms of
whooping cough.
Vaccinations
All healthy and infected children had received either the Dutch
whole-cell pertussis vaccine (DTwP-IPV- Hib, NVI, Bilthoven, the
Netherlands) or an acellular vaccine (DTaP-IPV- Hib, Infanrix-
IPV-Hib
TM, GlaxoSmithKline Biologicals S.A., Rixensart, Bel-
gium) at 2, 3, 4 and 11 months of age according to the NIP. The
Dutch wP vaccine was replaced by an aP vaccine in 2005.
Therefore, subgroups of children of 12 months of age had received
either 4 injections of wP or 4 of aP vaccines at 2, 3, 4 and 11
months of age and a third subgroup had received 3 wP
vaccinations at 2, 3 and 4 months of age and one aP vaccination
at 11 months of age. In children 4 years and older, an additional
preschool booster vaccination with either ACV-SB or Infanrix
TM
(both from GSK) or with Triaxis
TM (Sanofi Pasteur, Lille, France)
was administered at 4 years of age. ACV-SB and Infanrix
TM both
contained the same amounts of pertussis antigens (high-dose);
25 mg of PT, 25 mg of FHA and 8 mg of Prn, whereas Triaxis
TM
contained 2.5 mg of PT, 5 mg of FHA, 3 mg of Prn and 5 mgo f
combined fimbriae type 2 and 3 (Fim2/3) (low-dose) [14].
Children 9 years of age had received a second aP booster
vaccination, Boostrix-IPV
TM (GSK), that contained 8 mg of PT,
8 mg of FHA and 2.5 mg of Prn. Of the 73 children who had been
infected with B.pertussis, 71 children had been vaccinated
according to the NIP (63 wP primed children and 8 aP primed
children) and 2 children (7 and 8 years of age) had not received
any pertussis vaccination before infection.
Serological assays
For measurement of plasma IgA levels directed against the 3 B.
pertussis vaccine antigens (PT, FHA and Prn) the fluorescent bead-
based multiplex immunoassay (MIA) was used as previously
described [14,16] with some modifications. To prevent possible
inter-immunoglobulin isotype competition, plasma samples were
depleted of IgG by adding GullSORB (10:1 vol/vol) (meridian
Bioscience Inc., Cincinnati, OH). Moreover, 50 ml of a 1/100
dilution of Goat F(ab9)2-anti-Human IgA was added to each well
for 30 minutes before adding 50 ml R-Phycoerythrin conjugated
Goat anti-Mouse IgA (Southern Biotechnologies, Alabama). The
in-house reference serum was calibrated against the human
reference pertussis antiserum lot 3 for PT and FHA and lot 4
for Prn (CBER, FDA). Next to in-house controls in a single
dilution, a 3-fold serial dilution of the reference serum was added
over 8 wells on each plate. Serum IgA antibodies against a crude
cell-membrane preparation of B.pertussis were previously measured
with an in-house ELISA as described earlier [15].
B-cell isolation, stimulation and ELISPOT-assays
In 149 randomly selected healthy and infected children between
3 and 10 years of age (on average 10 per group, range 5–17), we
performed total IgA and at least one pertussis antigen-specific
enzyme-linked immunospot (ELISPOT)-assays as previously
described [17,18]. Plates were coated with 10 mg/ml anti-human
IgA-Fc-specific and incubated the plate with alkaline phosphatase
conjugated goat anti-human IgA for the detection of IgA-specific
memory B-cells to the pertussis antigens [17,18]. Mean spot values
of the non-coated wells were used as negative controls. From all
mean spot values of the antigen-coated wells per sample, the
negative controls were subtracted. The numbers of antigen-specific
IgA-memory B-cells were presented per 10
5 B-cells. Due to low
numbers of IgA antigen-specific memory B-cells, we presented the
percentage of children with at least 1 antigen-specific memory B-
cell and defined this as a positive memory B-cell response.
Statistical methods
Anti-PT, anti-FHA and anti-Prn IgA levels were expressed as
geometric mean concentrations (GMCs) with a 95% confidence
interval (CI). A positive IgA response was defined as an IgA level
above 1 EU/ml for PT, FHA and Prn. The Mann-Whitney-U-test
was used for comparison between the different groups. To analyze
the correlation between variables Spearman correlations (rs) and
linear regression analysis was used. P,0.05 was considered
significantly different.
Results
IgA levels after wP or aP vaccinations or pertussis
infection
Infected children showed significant higher IgA responses to
PT, FHA and Prn than both Dutch wP and aP primed healthy
children at 1, 3, 4, 6 and 9 years of age (figure 2). In addition, a
positive PT-, FHA- and Prn-specific IgA response was found in
84%, 78% and 80% of the infected children respectively, whereas
6%, 58% and 75% of the wP primed children aged 4 years and
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a positive IgA response at day 10 after the preschool booster
vaccination, respectively (data not shown). IgA responses to all 3
antigens were positive in 62% of the infected children, but only
9% of all wP primed children (pre- and post-booster) and in 0% of
all aP primed children. In wP primed children at 4 years of age
significantly higher post-booster FHA- and Prn-responses were
observed and at 6 years of age significantly higher FHA-responses
were shown compared with aP primed children of the same ages
(figure 2). Five years after the preschool booster at 4 years of age in
wP primed children of 9 years of age, anti-pertussis IgA responses
had returned to pre-booster levels. However, all pertussis-specific
IgA responses significantly increased after a second booster
vaccination at 9 years of age and after one-year follow-up anti-
FHA and anti-Prn IgA levels still significantly exceeded pre-
booster levels.
The effect of the time of blood sampling on IgA
responses
In infected children that were older than 4 years significantly
higher IgA responses to PT and FHA were observed compared
with children younger than 4 years, at least in those children
where blood sampling had occured within 30–60 days after the
start of clinical symptoms of whooping cough (table 1). After 60
days, GMCs of anti-PT, anti-FHA and anti-Prn IgA levels were
comparable in children above 4 years of age compared with those
younger than 4 years.
Correlation between IgA and IgG levels
High correlations between anti-PT, anti-FHA and anti-Prn IgA
and IgG levels were found in infected children and to some degree
in Dutch wP primed children, but not in aP primed children
(figure 3). For FHA and Prn, highest correlations were observed in
infected and wP primed children, while for PT only a high
correlation between IgA and IgG levels was found in infected
children. Low correlations for FHA and Prn were found in aP
primed children.
As IgA levels against pertussis crude cell-membranes (IgA-Bp)
were used for pertussis diagnostics in several countries, we
correlated these levels with our pertussis vaccine antigen-specific
IgA levels in infected children. No correlation between serum IgA-
Bp antibodies and serum IgA levels against PT was found, while
IgA-Bp levels correlated with anti-FHA IgA levels and to a lesser
extent with serum anti-Prn levels (figure 4).
Pertussis-specific IgA memory B-cells responses
The percentage of total IgA-producing memory B-cells in
infected children (on average 6.8%) was significantly higher than
in the healthy children (on average 3.0%). Also, the number of PT-
, FHA- and Prn-specific memory B-cells was significantly higher in
infected children as compared to healthy children. Between the
healthy Dutch wP and aP primed children of different ages, no
differences in percentages of total IgA-producing B-cells and no
differences in the number of PT-, FHA- and Prn-specific memory
B-cell responses were found (data not shown). In general, about
50% of the children showed a positive PT-, FHA- or Prn-specific
memory B-cell response (table 2). The majority of the Dutch wP
primed children at 9 years of age showed PT-, FHA- and Prn-
specific memory B-cells 28 days after the second booster
vaccination. Remarkably, 4/5 of the aP primed children at 4
years of age showed already FHA-specific memory B-cells even
before the preschool booster vaccination.
Discussion
In this study we showed an increased serum IgA level against
PT in vaccinated children who had recently been infected with
B.pertussis, but not in healthy aP vaccinated children and only in a
few Dutch wP vaccinated children. Remarkably, the high
Figure 1. The number of healthy children per age group. (A) children primed with the Dutch wP vaccine and (B) children primed with aP
vaccines.
doi:10.1371/journal.pone.0027681.g001
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infected children, but not in the healthy wP and aP vaccinated
children, strengthens the role of serum PT-specific IgA as a
diagnostic parameter for pertussis also in the vaccinated
population. We found that anti-PT IgA levels in serum had a
high specificity and a reasonable sensitivity. Since aP vaccinations
induce high levels of IgG antibodies against PT, the presence of
serum IgA-PT responses will help to differentiate between vaccine
induced antibody levels and those induced by natural infection.
Only 6% of the Dutch wP primed children showed a positive IgA-
response for PT shortly after the preschool booster with an aP
vaccine. Interestingly, this percentage is concurrent with the sero-
prevalence of pertussis in children in the Netherlands at the time
the study was conducted [19]. In these children who might have
been primed by previous exposure to B.pertussis leading to
(subclinical) infection, serum IgA-PT levels could consequently
have increased again after re-stimulation by booster vaccination.
The overall absence of anti-PT antibodies in aP primed children
suggests that infection has not occurred in these children. This
implicitly demonstrates that the implementation of the aP vaccine
for infant immunization has led to improved protection against
whooping cough in young children in the Netherlands as previous
data already suggested [19,20]. The absence of a dose-response
effect for IgA levels after pertussis booster vaccination with low or
high pertussis antigen content in both Dutch wP and aP primed
healthy children at 4 years of age actually emphasizes that priming
for pertussis-specific IgA responses is induced by infection rather
than by vaccination. Moreover, as 6% of the population is
suggested to be annually infected with B.pertussis [19], about half of
our wP primed children 9 years of age should show an elevated
serum IgA-PT level at one month after the booster as is confirmed
by our data (32/75 children 9 years of age).
The role for IgA levels against the other pertussis antigens FHA
and Prn in pertussis diagnostics remains controversial. Serum IgA
responses against FHA and Prn were not limited to the infected
children only, but were also observed in healthy Dutch wP primed
and to a lesser extent in healthy aP primed children. Moreover,
serum IgA responses against pertussis crude cell-membranes also
lack specificity and correlated with the B.pertussis non specific anti-
FHA levels, but only marginally with the B.pertussis specific anti-PT
levels. Since FHA and Prn are adhesion factors of B.pertussis, these
antibodies might illustrate the ongoing circulation of B.pertussis.
Moreover, while PT is a toxin unique to B.pertussis, Prn antigen
also belongs to other Bordetellae species [21] and other organisms
also induce FHA antibodies [22,23]. As our previous studies
already indicated [14,18] the Prn component in the aP vaccine
seemed to be highly immunogenic resulting in extremely high
IgG-Prn levels after aP vaccination. This high immunogenicity
may also explain the small increase in IgA-Prn levels observed in
several children in the aP vaccinated groups of 12 months and 6
years of age. The GMCs of the PT, FHA and Prn IgA antibodies
in the infected children are in agreement with those previously
measured in B.pertussis confirmed infected adults with unknown
pertussis vaccination-history [7,24]. Moreover, a small increase in
Figure 2. IgA levels. IgA responses specific for PT (A), FHA (B) and Prn
(C) for each child in the on the x-axis presented group of children. The
red horizontal bars indicate the GMC. The 10 and 28 days post-booster
responses are indicated by the black circles and all other groups are
indicate by open circles. * significant differences (p,0.05) are indicated
for the healthy children between the presented age groups in similar
primed children. Differences between infected children and the various
groups of healthy wP and aP primed children are described in
paragraph 3.1 of the results section.
doi:10.1371/journal.pone.0027681.g002
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IgA levels after an aP booster vaccination have also been observed
in some adolescents and adults [10,11,12] and are in line with our
findings in children.
It was previously suggested that serum IgA-PT antibodies
represent recent infection, but only 50% of children with pertussis
actually showed an IgA-PT response [25]. In an Australian study
the sensitivities of whole-cell, PT, FHA or Prn IgA assays varied
between 24% and 64% [4]. In our study, however, we found 80%
sensitivity of serum anti-PT IgA levels in pertussis infected children
that proved independent of the time of blood sampling. As the
MIA is a highly accurate and sensitive assay, even in the lower
limit of quantification, the minimal defined level of 1 EU/ml for a
positive IgA immune response is justified. Future monitoring of
serum IgA antibodies in the young aP primed population will be
useful to further corroborate the role of serum IgA antibodies in
single serum diagnostics for pertussis.
Surprisingly, despite lower serum anti-pertussis IgA levels in
healthy aP primed children compared with healthy wP primed
children, comparable numbers of children from both groups
showed detectable circulating pertussis-specific IgA memory B-
cells. Antigen-specific IgA memory B-cells are derived in the
mucosa associated lymphoid tissue and migrate via the blood to
the secretory effector sites, e.g. the oral mucosa where sIgA is
locally produced after antigen challenge [26]. This might explain
why both wP and aP vaccinated children have comparable
numbers of pertussis-specific IgA memory B-cells, since the contact
with B.pertussis will be similar for both groups due to the high
Table 1. The effect of the time of blood sampling since the start of pertussis symptoms on serum IgA responses to PT, FHA and
Prn in children younger and older than 4 years of age.
IgA-PT IgA-FHA IgA-Prn
Children ,4 years n= GMC 95% CI GMC 95% CI GMC 95% CI
Timepoint ,30 days 13 4.3 2.3–8.2 7.1 2.9–17.5 13.5 3.2–57.0
30–60 days 17 7.0 4.2–11.8 14.5 5.5–38.4 15.2 4.6–50.3
.60 days 9 3.6 1.2–11.1 18.8 1.1–336.2 16.5 0.9–310.5
Children .4 years n= GMC 95% CI GMC 95% CI GMC 95% CI
Timepoint ,30 days 13 11.5 4.4–29.7 16.6 5.0–55.4 11.7 5.5–25.0
30–60 days 11 14.8*# 8.9–24.4 93.8## 41.1–214.1 18.3 8.4–39.7
.60 days 12 3.4 1.1–10.4 14.6 1.3–163.7 21.5 3.3–139.2
*significantly higher as compared to .60 days GMC.
#significantly higher as compared to ,30 days GMC.
#significantly higher as compared to GMC at same time point in children ,4 years of age.
doi:10.1371/journal.pone.0027681.t001
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Correlations between serum IgA and IgG responses. Spearman correlations and linear regression analysis between serum IgA and
serum IgG responses specific for PT, FHA and Prn presented for infected (A), wP (B) and aP (C) primed children.
doi:10.1371/journal.pone.0027681.g003
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IgA responses were observed as compared to aP vaccinated
children, probably because infection with B.pertussis occurs more
frequently in this group. Moreover, we have previously shown that
some years after vaccination pertussis specific IgG memory B-cells
do not perse correlate with serum IgG levels [18]. In addition,
long-lived plasmacells home to the bone marrow and locally
produce background serum IgA levels [2]. However, it is unknown
Figure 4. Correlations between serum IgA-Bp and IgA-PT, -FHA and -Prn in infected children. Serum IgA-Bp levels are presented on the x-
axis and serum IgA-PT (A), -FHA (B) and -Prn (C) on the y-axis.
doi:10.1371/journal.pone.0027681.g004
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antigens or polyclonal stimulation or are a result of leakage from
the mucosal surfaces into the circulation [26]. Only one study from
20 years ago showed a correlation for FHA and PT between serum
IgA and IgA levels in saliva of pertussis-infected individuals. The
diagnostic value of salivary IgA seemed rather weak for pertussis
[27], whereas circulating pathogen-specific IgA antibodies might
reflect those at the mucosal surfaces as demonstrated for rotavirus
and poliovirus [28,29,30]. In general, mucosal IgA responses are
important in the protection against pathogens as found in
newborns and patients with IgA deficiency [31,32]. However,
the role for serum IgA in protection against whooping cough
remains unresolved. Murine studies showed that IgA exhibits
bactericidal effector functions [33], whereas IgA was not required
to clear B.pertussis [34]. In a recent murine study a superior
protection and promising long-term immune response was found
after a single intranasal dose of a live-attenuated B.pertussis vaccine,
named BPZE1, compared to parenterally administred aP vaccines
[35]. This suggest an important role for mucosal immune
responses in protection against pertussis infection. In our study
we found no serum IgA responses after aP vaccinations, whereas
protection against pertussis has improved after implementation of
these aP vaccines. Therefore, serum IgA antibodies do not seem to
be essential for pertussis protection after parentarelly administered
vaccines. However, after infection this situation might be different
and it is very likely that IgA antibodies play an important role in
the clearance of the infection at the mucosa. It will be important to
further elucidate anti-PT IgA levels in aP primed individuals who
have been infected, to prove the role for serum anti-PT IgA levels
in diagnostics. Moreover, the effect of different pertussis
vaccinations as well as natural infection on salivary IgA will be
important to further elucidate the role of mucosal IgA in
protection against whooping cough [31,32,33,34,35].
In conclusion, we demonstrated that a high specificity of serum
IgA levels against PT with a reasonable sensitivity recent pertussis
infection in Dutch wP and aP vaccinated children. While infection
induced anti-PT IgA antibodies, pertussis vaccines clearly did not.
Especially in the aP vaccinated population, serum IgA-PT
responses will be of great value for the diagnostics of pertussis. A
better understanding of serum and mucosal IgA responses and
their role in protection against whooping cough should finally
result in a further improvement of the pertussis vaccines for
infants.
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